(News Bulletin 247) – TheraVet reported Thursday growing interest in its program dedicated to canine bone cancer, including a sharp increase in the number of centers participating in the program.
Since the launch of the project, at the end of 2022, the number of participating centers has increased by 300% to reach the number of 16 in seven countries, indicates the veterinary biotechnology company.
Since its official launch two months ago, that number has increased by 33%, adds TheraVet.
Its osteosarcoma program consists of a minimally invasive limb-sparing solution that could be an alternative to amputation in dogs.
This component can also be combined with all non-surgical management options already available such as chemotherapy or radiotherapy.
With approximately 40,000 cases per year in Europe and the United States, osteosarcoma is a serious disease with a poor prognosis and severely affecting the quality of life of dogs due to intense pain and reduced mobility.
Following this announcement, TheraVet shares rose 0.5% on Thursday, after having taken up 10% in the early morning.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
